Related references
Note: Only part of the references are listed.Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid et al.
CLINICAL INFECTIOUS DISEASES (2016)
End TB with precision treatment!
Evelien P. M. van der Burgt et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics
Samiksha Ghimire et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis
Marlanka A. Zuur et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Sensititre MycoTB Plate Compared to Bactec MGIT 960 for First- and Second-Line Antituberculosis Drug Susceptibility Testing in Tanzania: a Call To Operationalize MICs
Scott K. Heysell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Christoph Lange et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
Junichi Azuma et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
D. H. Vu et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid
PR Donald et al.
CLINICAL INFECTIOUS DISEASES (2004)
Share Paper
